Farletuzumab
- Generic Name
- Farletuzumab
- Drug Type
- Biotech
- CAS Number
- 896723-44-7
- Unique Ingredient Identifier
- 2O09BG0OWA
- Background
Farletuzumab (MORAb-003) is a fully humanized monoclonal antibody against the folate receptor alpha, for the potential treatment of epithelial ovarian cancer.
- Indication
Investigated for use/treatment in ovarian cancer.
Datopotamab Deruxtecan's Role in HR+/HER2- Breast Cancer Treatment: Sequencing and Safety Considerations
• Datopotamab deruxtecan (Dato-DXd) is poised to become a standard treatment for metastatic hormone receptor-positive, HER2-negative breast cancer after prior systemic therapy.
• Optimal sequencing of antibody-drug conjugates (ADCs) like Dato-DXd, sacituzumab govitecan, and trastuzumab deruxtecan remains uncertain, especially considering overlapping toxicities.
• Real-world toxicity profiles suggest sacituzumab govitecan may cause more cytopenias and diarrhea, while Dato-DXd and trastuzumab deruxtecan are linked to interstitial lung disease.
• The lack of overall survival difference in the TROPION-Breast01 trial raises questions about efficacy issues or the impact of crossover between treatment arms.
EU Approves AbbVie's Elahere for Platinum-Resistant Ovarian Cancer
• AbbVie's Elahere (mirvetuximab soravtansine) receives EU approval for folate receptor-alpha (FRα) positive, platinum-resistant ovarian cancer, marking a significant advancement in treatment options.
• Elahere is the first antibody-drug conjugate (ADC) approved in the EU for this indication, demonstrating improved overall survival compared to chemotherapy in the MIRASOL trial.
• The approval addresses a critical unmet need, as it ends a decade-long gap in new treatments for platinum-resistant ovarian cancer in the EU, offering hope for improved outcomes.
• This approval, based on the MIRASOL trial, showed a 33% reduction in the risk of death and a 35% improvement in progression-free survival compared to chemotherapy.
Targeted Therapies Show Promise in High-Grade Serous Ovarian Cancer Treatment
• Traditional treatments for high-grade serous ovarian cancer, involving surgery and platinum-based chemotherapy, often lead to resistance, necessitating targeted therapies.
• PARP inhibitors and anti-angiogenic agents like bevacizumab have improved upfront therapy, but other targeted approaches, including immunotherapy, have shown limited success.
• Emerging therapeutic targets, such as tyrosine kinase inhibitors and lipid metabolism agents, are under investigation to combat this aggressive cancer.
• Ongoing research explores gene therapy and ribosome-targeted drugs as potential modalities to enhance treatment outcomes for high-grade serous ovarian cancer.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath